Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: A meta-analysis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Qu, Hong Chen ^a   Zhang, Wei ^a   Yan, Shi ^b   Liu, Yi Li ^a   Wang, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Burn Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NERVE GROWTH FACTOR; CREATININE;

ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; INTERSTITIAL CYSTITIS; OVERACTIVE BLADDER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN URINE LEVEL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; CASE CONTROL STUDY; CYSTITIS, INTERSTITIAL; META ANALYSIS; PUBLISHING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINE;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CREATININE; CYSTITIS, INTERSTITIAL; HUMANS; NERVE GROWTH FACTOR; PUBLICATION BIAS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 84929218793     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106321     Document Type: Article

References (37)

1. Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg L Jr (1999) The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol 161: 553-557.
2. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, et al. (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20: 327-336. (Pubitemid 44175300)
3. Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Brown SO, Gao SY, et al. (2005) Prevalence of interstitial cystitis symptoms in a managed care population. J Urol 174: 576-580. (Pubitemid 40981606)
4. Hanno PM, Sant GR (2001) Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology 57: 2-6. (Pubitemid 33733958)
5. Messing EM (1987) The diagnosis of interstitial cystitis. Urol 2: 4-7.
6. Bhide AA, Cartwright R, Khullar V, Digesu GA (2013) Biomarkers in overactive bladder. Int Urogynecol J 24: 1065-1072.
7. Steers WD, Tuttle JB (2006) Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract. Urol 3: 101-110. (Pubitemid 43239267)
8. Steers WD, Kolbeck S, Creedon D, Tuttle JB (1991) Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 88: 1709-1715.
9. Tuttle JB, Steers WD, Albo M, Nataluk E (1994) Neural input regulates tissue NGF and growth of the adult rat urinary bladder. J Auton Nerv Syst 49: 147-158. (Pubitemid 24251643)
10. Vizzard MA (2001) Alterations in neuropeptide expression in lumbosacral bladder pathways following chronic cystitis. J Chem Neuroanat 21: 125-138. (Pubitemid 32324236)
11. Dupont MC, Spitsbergen JM, Kim KB, Tuttle JB, Steers WD (2001) Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 166: 1111-1118. (Pubitemid 32751054)
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 18: 800-804. (Pubitemid 350295184)
13. Murphy GK, McAlister FA, Weir DL, Tjosvold L, Eurich DT (2014) Cardiovascular medication utilization and adherence among adults living in rural and urban areas: a systematic review and meta-analysis. BMC Public Health 14: 544.
14. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
15. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137.
16. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. (Pubitemid 43209069)
17. Liu HT, Tyagi P, Chancellor MB, Kuo HC (2009) Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 104: 1476-1481.
18. Liu HT, Tyagi P, Chancellor MB, Kuo HC (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106: 1681-1685.
19. Pinto R, Lopes T, Frias B, Silva A, Silva JA, et al. (2010) Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 58: 360-365.
20. Kuo HC, Liu HT, Chancellor MB (2010) Urinary nerve growth factor is a better biomarker than detrusor Wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 29: 482-487.
21. Chung SD, Liu HT, Lin H, Kuo HC (2011) Elevation of serum C-Reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 30: 417-420.
22. Liu HT, Kuo HC (2012) Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLOS ONE 7: e44687.
23. Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor MB, et al. (2012) Urinary Chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol 187: 2243-2248.
24. Corcoran AT, Yoshimura N, Tyagi V, Jacobs B, Leng W, et al. (2013) Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol 31: 241-246.
25. Jiang YH, Liu HT, Kuo H-C (2014) Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. PLOS ONE 9: e91609.
26. Erickson DR, Xie SX, Bhavanandan VP, Wheeler MA, Hurst RE, et al. (2002) A comparison of multiple urine markers for interstitial cystitis. J Urol 167: 2461-2469. (Pubitemid 34533146)
27. Saini R, Gonzalez RR, Te AE (2008) Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link. Curr Urol Rep 9: 314-319.
28. Ogawa T, Homma T, Igawa Y, Seki S, Ishizuka O, et al. (2010) CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol 183: 1206-1212.
29. Vizzard MA (2000) Alterations in spinal cord Fos protein expression induced by bladder stimulation following cystitis. Am J Physiol Regul Integr Comp Physiol 278: R1027-R1039. (Pubitemid 30215217)
30. Amaya F, Shimosato G, Nagano M, Ueda M, Hashimoto S, et al. (2004) NGF and GDNF differentially regulate TRPV1 expression that contributes to development of inflammatory thermal hyperalgesia. Eur J Neurosci 20: 2303-2310. (Pubitemid 39472393)
31. Steers WD (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4: S7-18.
32. Lamb K, Gebhart GF, Bielefeldt K (2004) Increased nerve growth factor expression triggers bladder overactivity. J Pain 5: 150-156. (Pubitemid 38879393)
33. Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, et al. (1997) Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 79: 572-577. (Pubitemid 28321098)
34. Liu HT, Kuo HC (2007) Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 70: 463-468.
35. Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, et al. (2001) The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol 165: 975-979. (Pubitemid 32156334)
36. Okragly AJ, Niles AL, Saban R, Schmidt D, Hoffman RL, et al. (1999) Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol 161: 438-441.
37. Rachaneni S, Arya P, Latthe P (2013) Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review. Int Urogynecol J 24: 1603-1609.